User login
Article Type
Changed
Thu, 12/15/2022 - 18:03
Display Headline
ASCO 2015: from data and learning, to daily practice
The 2015 annual meeting of the American Society for Clinical Oncology, themed “Illumination and innovation: transforming data into learning,” brought together more than 37,000 attendees in Chicago and featured numerous clinical advances that will improve the lives of our cancer patients. That said, to a first-timer, the gathering probably would have felt like an update on using the immune system to fight cancer, despite our more than 30 years of using such strategies. The science behind the development of these promising monoclonal antibodies is outstanding, and the impact will certainly be far reaching.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(7)
Page Number
235-236
Legacy Keywords
monoclonal antibodies, immunotherapy, nivolumab, ipilimumab, metastatic melanoma, PD-L1, programmed cell death ligand-1, docetaxel, advanced prostate cancer, nonsquamous lung cancer, head and neck cancer, HPV-positive, ado-trastuzumab, T-DM1, aspirin, colon cancer
Sections
Article PDF
Article PDF
The 2015 annual meeting of the American Society for Clinical Oncology, themed “Illumination and innovation: transforming data into learning,” brought together more than 37,000 attendees in Chicago and featured numerous clinical advances that will improve the lives of our cancer patients. That said, to a first-timer, the gathering probably would have felt like an update on using the immune system to fight cancer, despite our more than 30 years of using such strategies. The science behind the development of these promising monoclonal antibodies is outstanding, and the impact will certainly be far reaching.
Click on the PDF icon at the top of this introduction to read the full article.
The 2015 annual meeting of the American Society for Clinical Oncology, themed “Illumination and innovation: transforming data into learning,” brought together more than 37,000 attendees in Chicago and featured numerous clinical advances that will improve the lives of our cancer patients. That said, to a first-timer, the gathering probably would have felt like an update on using the immune system to fight cancer, despite our more than 30 years of using such strategies. The science behind the development of these promising monoclonal antibodies is outstanding, and the impact will certainly be far reaching.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 13(7)
Issue
The Journal of Community and Supportive Oncology - 13(7)
Page Number
235-236
Page Number
235-236
Article Type
Display Headline
ASCO 2015: from data and learning, to daily practice
Display Headline
ASCO 2015: from data and learning, to daily practice
Legacy Keywords
monoclonal antibodies, immunotherapy, nivolumab, ipilimumab, metastatic melanoma, PD-L1, programmed cell death ligand-1, docetaxel, advanced prostate cancer, nonsquamous lung cancer, head and neck cancer, HPV-positive, ado-trastuzumab, T-DM1, aspirin, colon cancer
Legacy Keywords
monoclonal antibodies, immunotherapy, nivolumab, ipilimumab, metastatic melanoma, PD-L1, programmed cell death ligand-1, docetaxel, advanced prostate cancer, nonsquamous lung cancer, head and neck cancer, HPV-positive, ado-trastuzumab, T-DM1, aspirin, colon cancer
Sections
Citation Override
JCSO 2015;13:235-236
Disallow All Ads
Alternative CME
Article PDF Media
Document